EPISODE · Jul 1, 2026 · 7 MIN
Imugene CEO on Phase 1b azer-cel data: second complete response
from Proactive - Interviews for investors · host Proactive Investors
Imugene Ltd MD and CEO Leslie Chong talked with Proactive about the company reporting a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial. The latest response was recorded in the first mantle cell lymphoma, or MCL, patient treated in the azer-cel Phase 1b study. The patient had previously received and failed BTKi therapy before achieving a complete response at the Day 28 assessment. The result follows closely after Imugene Ltd reported its first complete response in the concurrent BTKi cohort, highlighting a second early response in a patient group that has relapsed on or is refractory to BTKi therapy. Chong said MCL can be an aggressive disease and that patients who progress after BTKi therapy can face a steep decline. azer-cel is being studied in combination with an existing approved therapy, to help make BTKi treatment work again. She also discussed increased business development activity and ongoing conversations with pharmaceutical companies, describing collaboration and partnering as the organic next stage of development. Visit Proactive’s YouTube channel for more videos, and don’t forget to give this video a like, subscribe to the channel and enable notifications for future content. #Imugene #IMU #IUGNF #azerCel #BTKi #BrutonTyrosineKinase #MantleCellLymphoma #MCL #BloodCancer #Lymphoma #ClinicalTrial #Biotech #ASXStocks #OTCStocks #BiotechInvesting #ProactiveInvestors
What this episode covers
Imugene Ltd MD and CEO Leslie Chong talked with Proactive about the company reporting a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial. The latest response was recorded in the first mantle cell lymphoma, or MCL, patient treated in the azer-cel Phase 1b study. The patient had previously received and failed BTKi therapy before achieving a complete response at the Day 28 assessment. The result follows closely after Imugene Ltd reported its first complete response in the concurrent BTKi cohort, highlighting a second early response in a patient group that has relapsed on or is refractory to BTKi therapy. Chong said MCL can be an aggressive disease and that patients who progress after BTKi therapy can face a steep decline. azer-cel is being studied in combination with an existing approved therapy, to help make BTKi treatment work again. She also discussed increased business development activity and ongoing conversations with pharmaceutical companies, describing collaboration and partnering as the organic next stage of development. Visit Proactive’s YouTube channel for more videos, and don’t forget to give this video a like, subscribe to the channel and enable notifications for future content. #Imugene #IMU #IUGNF #azerCel #BTKi #BrutonTyrosineKinase #MantleCellLymphoma #MCL #BloodCancer #Lymphoma #ClinicalTrial #Biotech #ASXStocks #OTCStocks #BiotechInvesting #ProactiveInvestors
NOW PLAYING
Imugene CEO on Phase 1b azer-cel data: second complete response
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.